CAD in Chronic Kidney Disease. Kuang-Te Wang

Similar documents
Cardiovascular Disease in CKD. Parham Eftekhari, D.O., M.Sc. Assistant Clinical Professor Medicine NSUCOM / Broward General Medical Center

FFR in Multivessel Disease

How do We Manage Coronary Artery Disease in Patients with CKD and ESRD?

Acute Coronary Syndrome. Cindy Baker, MD FACC Director Peripheral Vascular Interventions Division of Cardiovascular Medicine

UPDATES FROM THE 2018 ANTIPLATELET GUIDELINES

What oral antiplatelet therapy would you choose? a) ASA alone b) ASA + Clopidogrel c) ASA + Prasugrel d) ASA + Ticagrelor

03/07/ Background. + High Risk Features Are Prevalent in Dialysis Patients

PCI for Left Main Coronary Artery Stenosis. Jean Fajadet Clinique Pasteur, Toulouse, France

Imaging ischemic heart disease: role of SPECT and PET. Focus on Patients with Known CAD

EAE Teaching Course. Magnetic Resonance Imaging. Competitive or Complementary? Sofia, Bulgaria, 5-7 April F.E. Rademakers

Safety of Single- Versus Multi-vessel Angioplasty for Patients with AMI and Multi-vessel CAD

Cardiovascular Evaluation in Preparation for Renal Transplantation

Screening for Asymptomatic Coronary Artery Disease: When, How, and Why?

Ischemic and bleeding risk stratification in NSTE ACS. Andrzej Budaj Postgraduate Medical School Grochowski Hospital, Warsaw, Poland

Impact of coronary atherosclerotic burden on clinical presentation and prognosis of patients with coronary artery disease

Cardiogenic Shock. Carlos Cafri,, MD

Coronary interventions

Diabetes and Occult Coronary Artery Disease

( 1) Framingham Heart

Pathophysiology of Coronary Microvascular Dysfunction

Σεμινάριο Ομάδων Εργασίας Fractional Flow Reserve (FFR) Σε ποιούς ασθενείς; ΔΗΜΗΤΡΗΣ ΑΥΖΩΤΗΣ Επιστ. υπεύθυνος Αιμοδυναμικού Τμήματος, Βιοκλινική

Stable Ischemic Heart Disease. Ivan Anderson, MD RIHVH Cardiology

The use of Cardiac CT and MRI in Clinical Practice

DIFFERENTIATING THE PATIENT WITH UNDIFFERENTIATED CHEST PAIN

Peri-operative Troponin Measurements - Pathophysiology and Prognosis

Case Challenges in ACS The Very Elderly in the Cath Lab

Evidence-Based Management of CAD: Last Decade Trials and Updated Guidelines

VCU Pauley Heart Center: A 2009 US News Top 50 Heart and Heart Surgery Hospital

Analysis of Coronary Artery Disease and Associated Risk Factors in Patients with Chronic Kidney Disease

Microvascular Disease: How to Diagnose and What s its Treatment

The best from Euro-Echo Ischemic heart disease. Fausto Rigo,FESC Department of Cardiology Mestre-Venezia Hospital,Italy

Intervention: How and to which extent is technology helping us?

The cardiologist s interest in renal function

CLINICAL CONSEQUENCES OF THE

Invited Experts' Case Presentation and 5-Slides Focus Review

Supplementary Online Content

CKD and CVD. Jamal Salameh, MD, FACP, FASN First Coast Nephrology

Cardiovascular Mortality: General Population vs ESRD Dialysis Patients

FFR-Guided PCI. 4 th Imaging and Physiology Summit October 29 th, 2010 Seoul, Korea. Stanford

Indications of Coronary Angiography Dr. Shaheer K. George, M.D Faculty of Medicine, Mansoura University 2014

Maria Angela S. Cruz-Anacleto, MD

Dual Antiplatelet Therapy Made Practical

New Insight about FFR and IVUS MLA

Acute Coronary Syndromes. January 9, 2013 Chris Chiles M.D. FACC

MPS and Calcium Score in asymptomatic patient F. Mut, J. Vitola

Clinical Seminar. Which Diabetic Patient is a Candidate for Percutaneous Coronary Intervention - European Perspective

CURRENT STATUS OF STRESS TESTING JOHN HAMATY D.O.

Who Cares About the Past?

In-Ho Chae. Seoul National University College of Medicine

Incidence and Prevalence of Atherosclerotic Renal Artery Stenosis (RAS) in Patients with Coronary Artery Disease (CAD)

Mid-term results from real-world REPARA registry. Felipe Hernandez, on behalf of the REPARA investigators

Disclosures. Theodore A. Bass MD, FSCAI. The following relationships exist related to this presentation. None

Review of Cardiac Imaging Modalities in the Renal Patient. George Youssef

Novel Risk Markers in ACS (Hyperglycemia, Anemia, GFR)

Revascularization In HFrEF: Are We Close To The Truth. Ali Almasood


Evaluating Clinical Risk and Guiding management with SPECT Imaging

Left ventricular hypertrophy: why does it happen?

Perioperative Myocardial Infarction

2/20/2013. Why use imaging in CV prevention? Update on coronary CTA in 2013 Coronary CTA for 1 0 prevention: pros and cons Are we there yet?

Radial Artery Access Improving Outcomes and Decreasing Costs

Surgical vs. Percutaneous Revascularization in Patients with Diabetes and Acute Coronary Syndrome

TAVR in patients with. End-Stage CKD or in Renal Replacement Therapy:

How will new high sensitive troponins affect the criteria?

ESC CONGRESS 2010 Stockholm, august 28 september 1, 2010

Effects of Kidney Disease on Cardiovascular Morbidity and Mortality

Women and Ischemic Heart Disease Lessons Learned

OBJECTIVES. New Twist To Old Disease: Cardiovascular Update /9/2017. Prevention Pre-operative Coronary Artery Disease

Post-Procedural Myocardial Injury or Infarction

Ventricular tachycardia and ischemia. Martin Jan Schalij Department of Cardiology Leiden University Medical Center

Fractional Flow Reserve: Basics, FAME 1, FAME 2. William F. Fearon, MD Associate Professor Stanford University Medical Center

Benefit of Performing PCI Based on FFR

Antiplatelet Therapy in Primary CVD Prevention and Stable Coronary Artery Disease. Καρακώστας Γεώργιος Διευθυντής Καρδιολογικής Κλινικής, Γ.Ν.

Belinda Green, Cardiologist, SDHB, 2016

The Value of Stress MRI in Evaluation of Myocardial Ischemia

Measuring Natriuretic Peptides in Acute Coronary Syndromes

Acute Coronary Syndromes

Cardiovascular Complications Of Chronic Kidney Disease. Dr Atir Khan Consultant Physician Diabetes & Endocrinology West Wales Hospital, Carmarthen

Diabetic Patients: Current Evidence of Revascularization

STEMI update. Vijay Krishnamoorthy M.D. Interventional Cardiology

Approach to Multi Vessel disease with STEMI

Observational comparative effectiveness research using large databases

What is the Optimal Triple Anti-platelet Therapy Duration in Patients with Acute Myocardial Infarction Undergoing Drug-eluting Stents Implantation?

I have no financial disclosures

Clinical Lessons from BMC2-PCI

Assessing Myocardium at Risk: Applying SYNTAX

Supplementary Online Content

Chest pain and troponins on the acute take. J N Townend Queen Elizabeth Hospital Birmingham

Perioperative Infarcts: Epidemiology, predictors and post-op monitoring

New insights in stent thrombosis: Platelet function monitoring. Franz-Josef Neumann Herz-Zentrum Bad Krozingen

Survival of Patients on the Kidney Transplant Wait List: Relationship to Cardiac Troponin T

New Paradigms in Predicting CVD Risk

Why Cardiac MRI? Presented by:

The Future of Oral Antiplatelets in PAD and CAD Christopher Paris, MD, FACC, FSCAI

Current and Future Imaging Trends in Risk Stratification for CAD

A: Epidemiology update. Evidence that LDL-C and CRP identify different high-risk groups

Risk Stratification for CAD for the Primary Care Provider

Coronary Artery Disease in the 21 st Century: An Integrated Approach Based on Science and Art

Spontaneous Coronary Artery Dissection

Chronic Total Occlusion: A case for coronary artery bypass grafting

Transcription:

CAD in Chronic Kidney Disease Kuang-Te Wang

InIntroduction What I am going to talk about: CKD and its clinical impact on CAD Diagnosis of CAD in CKD PCI / Revasc Outcomes in CKD

CKD PCI CAD

Ohtake T, Kobayashi S, Moriya H et al. High prevalence of occult coronary artery stenosis in patients Incidence and severity of CAD increases as GFR decrea Nakano T, Ninomiya T, Sumiyoshi S et al. Association of kidney function with coronary atherosclerosis calcification in autopsy samples from Japanese elders: the Hisayama study. Am J Kidney Dis 2010; 5 Chonchol M, Whittle J, Desbien A et al. Chronic kidney disease is associated with angiographic coron artery disease. Am J Nephrol 2008; 28: 354 360. Diffuse multivessel involvement with calcification Ix JH, Shlipak MG, Liu HH et al. Association between renal insufficiency and inducible ischemia in pat with coronary artery disease: the heart and soul study. J Am Soc Nephrol 2003; 14: 3233 3238. Among pts with CAD, presence of CKD portends a wors CV prognosis Joki N, Hase H, Nakamura R et al. Onset of coronary artery disease prior to initiation of haemodialysis patients with end-stage renal disease. Nephrol Dial Transplant 1997; 12: 718 723.

n a series of consecutive incident dialysis patients who underwent cardiac atheterization, more than 60% of patients ad significant CAD (defined as more than 5% narrowing of a major coronary artery), ith an average of 3.3 lesions per patient.

Standard CVRFs are common in CKD + CAD setting Longenecker JC, Coresh J, Powe NR et al. Traditional cardiovascular disease risk factors in dialysis p compared with the general population: the CHOICE Study. J Am Soc Nephrol 2002; 13: 1918 1927. Weiner DE, Tighiouart H, Elsayed EF et al. The Framingham predictive instrument in chronic kidney d Am Coll Cardiol 2007; 50:217 224. Oxidative stress & inflammation linked to pathogenesis of plaque formation and rupture, as is mineralocorticoid excess defilippi C, Wasserman S, Rosanio S et al. Cardiac troponin T and C-reactive protein for predicting pr coronary atherosclerosis, and cardiomyopathy in patients undergoing long-term hemodialysis. JAMA 2 290: 353 359 Weiner DE, Tighiouart H, Elsayed EF et al. Inflammation and cardiovascular events in individuals with without chronic kidney disease. Kidney Int 2008; 73: 1406 1412 Menon V, Greene T, Wang X et al. C-reactive protein and albumin as predictors of all-cause and cardiovascular mortality in chronic kidney disease. Kidney Int 2005; 68: 766 772

Ooi et al., approximately 29% of patients ithout overt acute coronary disease had an levated level of troponin T. [13] Furthermore, ly about 11% of patients had concentrations less than 0.01 g/l.

Disordered mineral and bone metabolism accelerates C burden Giovannucci E, Liu Y, Hollis BW et al. 25-Hydroxyvitamin D and risk of myocardial infarction in men: a prospective study. Arch Intern Med 2008; 168: 1174 1180. Kovesdy CP, Ahmadzadeh S, Anderson JE et al. Association of activated vitamin D treatment and mo chronic kidney disease. Arch Intern Med 2008; 168: 397 403. Gutierrez OM, Mannstadt M, Isakova T et al. Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis. N Engl J Med 2008; 359: 584 592. CKD pts with clinical IHD symptoms may not have significant epicardial CAD Rostand SG, Kirk KA, Rutsky EA. Dialysis-associated ischemic heart disease: insights from coronary angiography. Kidney Int. 1984;25: 653 659.

Diagnosis of CAD in CKD

SCREENING AND DIAGNOSIS Who should be screened?

SCREENING AND DIAGNOSIS (K/DOQI guidelines) All patients upon initiation of renal replacement therapy, independent of symptoms. Kidney transplant wait list patients should be re-evaluated at intervals ranging from every year to every three years. Change in symptoms and signs, including recurrent hypotension, heart failure that is unresponsive to changes in dry weight,

SCREENING AND DIAGNOSIS Base line ECG and ECHO for all patients. Exercise or pharmacologic stress Echo: the K/DOQI guidelines state that dobutamine Echo was more sensitive in diagnosing obstructive coronary artery disease in the dialysis population. nuclear imaging-based stress testing Angiography: should be considered in dialysis patients who are candidates for coronary interventions and have positive

ST elevation, the most striking electrical sign of ischemia in patients with an MI, is 50% less frequent in those on dialysis versus the nondialysis population

compared with the general population, echocardiographic and nuclear imaging-based stress testing do appear to rform relatively well as prognostic tools and have at least moderate sensitivity for the detection of advanced obstructive CAD in dialysis patients.

Contrast enhanced cardiac magnetic resonance imaging allows for very sensitive detection of focal myocardial necrosis or fibrosis,

computed tomography angiography may also allow for noninvasive detection of obstructive coronary disease. However, neither computed tomography angiography nor cardiac magnetic resonance imaging have emerged as standard clinical tools

PCI in ACS + CKD

Coronary artery disease contributes to 40% to 50% of deaths among patients who receive dialysis. Approximately 10%-20% of these deaths are due to acute myocardial infarction (AMI) which tends to occur shortly after the initiation of dialysis with 29% within 1 year and 52% within 2 years

5 yrs mortality about 70-90%

Br J Cardio 2013;2

PCI in Stable CAD + CKD

3 yrs mortality 30-40

PCI in Stable CAD + CKD

Survival Curve Reference Group No Dialysis CKD Dialysis CKD

Stable CAD CKD Tex Heart Inst J 2010;37(1

PCI = CABG

Questions, questions CKD vs ESRD is there a difference for those already on dialysis? PCI vs CABG; DES vs BMS Multivessel / LM CAD; CTO management New PCI devices (rotablation, 3 rd /4 th Gen DES) and antithrombotics (ticagrelor, prasugrel) STE ACS vs NSTE ACS vs Stable CAD The anemia conundrum strategies (bivalirudin vs heparin DAPT duration, transfusion / Hb target, femoral vs radial)

CKD PCI CAD

The End